Oxbryta (Voxelotor) is a hemoglobin S polymerization inhibitor used for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older.
Dosage: The recommended voxelotor dose is 1,500 mg administered orally once daily with or without food. If a dose of voxelotor tablets is missed, continue dosing with voxelotor on the day following the missed dose. Patients should swallow voxelotor tablets whole. Do not cut/crush/chew the voxelotor tablets. It may be administered either with or without hydroxyurea.
Side Effects: The most commonly reported voxelotor side effects include:
- Stomach (abdominal) pain
Warnings and Precautions:
- The voxelotor uses are contraindicated in patients with known history of severe drug hypersensitivity reaction to it.
- Before starting therapy with voxelotor tablets, inform your healthcare practitioner if you are pregnant or plan to become pregnant.
- Patients with exchange transfusions are apprised to discuss with their doctor about possible difficulties with the interpretation of some blood tests when taking oxbryta 500 mg tablets.
- Nursing women are advised not to breastfeed while they are on the therapy with voxelotor 500 mg tablets.